| Hans-Günter Meyer-Thompson | HIV
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax, Paul E et al.
The Lancet , Volume 0 , Issue 0 , Published: 31 August 2017, doi.org/10.1016/S0140-6736(17)32340-1
Abstract
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32340-1/fulltext